Latest Pharmaceuticals News

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Mont Royal Resources has identified significant high-grade fluorspar mineralisation up to 39.8% CaF2 at its Mallard Prospect, located just 1.4km from the flagship Ashram Deposit in Québec. The discovery highlights expanding fluorspar potential amid tightening global markets and China's shift to net importer status.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

Mayne Pharma has been awarded $13.27 million in legal costs by the Supreme Court of New South Wales after successfully defending against Cosette Pharmaceuticals’ claims tied to a terminated acquisition deal.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Island Pharmaceuticals has appointed Raymond Taylor, a former BioCryst executive with deep Galidesivir expertise and US government funding experience, to accelerate development and procurement efforts for its broad-spectrum antiviral amid rising viral threats.